Rockefeller Capital Management L.P. Purchases 6,678 Shares of Guardant Health, Inc. $GH

Rockefeller Capital Management L.P. increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 135.2% in the fourth quarter, HoldingsChannel reports. The firm owned 11,618 shares of the company’s stock after purchasing an additional 6,678 shares during the period. Rockefeller Capital Management L.P.’s holdings in Guardant Health were worth $1,187,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in GH. Vanguard Group Inc. boosted its position in Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Franklin Resources Inc. raised its position in Guardant Health by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after purchasing an additional 435,232 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock worth $328,297,000 after purchasing an additional 277,001 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its stake in shares of Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Trading Up 13.8%

Guardant Health stock opened at $170.77 on Thursday. The company has a market cap of $22.64 billion, a PE ratio of -50.37 and a beta of 1.59. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $172.61. The company’s 50-day moving average is $116.77 and its two-hundred day moving average is $105.20.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of Guardant Health stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Musa Tariq sold 1,951 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $255,893.16. Following the sale, the director owned 11,048 shares of the company’s stock, valued at $1,449,055.68. The trade was a 15.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 712,513 shares of company stock valued at $90,921,587 over the last 90 days. Company insiders own 5.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on GH shares. Mizuho upped their price target on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Barclays boosted their target price on shares of Guardant Health from $120.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Guggenheim increased their price target on shares of Guardant Health from $135.00 to $160.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $146.18.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.